key: cord-1049619-wj2vuow9
authors: Shakoei, Safoura; Ghanadan, Alireza; Hamzelou, Shahin
title: Pustular psoriasis exacerbated by COVID‐19 in a patient with the history of psoriasis
date: 2020-11-05
journal: Dermatol Ther
DOI: 10.1111/dth.14462
sha: e6c1cad5f4ed9d9f4baf2002efa4f83a2c737340
doc_id: 1049619
cord_uid: wj2vuow9

nan

The recent coronavirus disease (COVID-19), which was first reported in China, has spread around the world, causing major public health concerns. 1 Several treatments have been proposed for the treatment of COVID-19, including hydroxychloroquine, monoclonal antibodies, corticosteroids, favipiravir, lopinavir/ritonavir, anticoagulants, and azithromycin. 2 Here, we present a case of pustular psoriasis, exacerbated by COVID-19 in a patient with a history of hydroxychloroquine use. Patient consent for publication is achieved.

The patient was a 47-year-old woman, presenting with pustular lesions over the past 3 weeks. The COVID-19 symptoms, including sore throat, myalgia, fever, and dry cough (for 8 days), had developed over the past 6 weeks. The chest computed tomography (CT) scan showed bilateral peripheral ground-glass opacities and infiltrations. 

Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Treatment algorithm for COVID-19: a multidisciplinary point of view

A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic?

Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment

Covid-19 and exacerbation of psoriasis

Guttate psoriasis secondary to COVID-19